Compare Charles River Laboratories Intl. Inc (CRL) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Grab Holdings Ltd. — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while Grab Holdings Ltd. trades at $3.79 (market cap $15.54B). The key difference: Grab Holdings Ltd. is the larger of the two by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals.
| CRL | GRAB | |
|---|---|---|
Market Cap | $11.14B | $15.54B |
Sector | Health | Technology |
52-Week High | $233.60 | $6.45 |
52-Week Low | $145.57 | $3.27 |
Enterprise Value | $14.00B | $11.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
GRAB trades at $3.94, up 0.25% on the day, with a bullish technical signal and strong analyst support. The company achieved profitability in 2025 with $268M net income and 7.95% margin, showing significant improvement from prior losses. Revenue growth continues, reaching $3.37B in 2025. Recent news highlights market outperformance and investor attention, though the stock reacted negatively to Uber CEO's board departure in early July 2026.
Outlook remains positive with 91.67% analyst buy ratings and $5.45 consensus target, implying 38% upside. Key risks include competitive pressures in ride-hailing, execution challenges in expanding financial services, and potential market volatility. Profitability trajectory and cash flow sustainability are critical for maintaining investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
